Compare Estee Lauder Companies Inc (EL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Incyte Corporation — how do they compare? Estee Lauder Companies Inc trades at $87.54 (market cap $31.76B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EL | INCY | |
|---|---|---|
Market Cap | $31.76B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $129.93 |
52-Week Low | $67.23 | $81.61 |
Enterprise Value | $37.93B | $20.04B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $87.70, up 0.58% on the day, with a bullish technical signal from moving averages and a consensus price target of $91.67. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.13 billion for 2025. Revenue has declined from $17.7 billion in 2022 to $14.33 billion in 2025, but positive cash flow from operations of $1.27 billion provides liquidity. A new fragrance launch and executive appointment signal ongoing brand development efforts.
The stock presents a mixed outlook. Analyst sentiment is divided with a slight Hold bias, yet technical momentum and earnings beats offer near-term upside potential. Key risks include sustained negative net income margins, high debt levels, and competitive pressures in the beauty sector. The upcoming Q2 2026 earnings report on August 19, 2026, will be critical for validating the recent positive earnings trend and guiding future price direction.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
